10-K/A: OPKO Health Files Amended 10-K to Correct Exhibit and Include XBRL Tagging
10-K/A Amendment
OPKO Health files an amendment to its 2024 annual report to correct an exhibit and include XBRL tagging.
Summary
- OPKO Health, Inc. is filing Amendment No. 1 on Form 10-K/A to amend and restate Part III, Item 10 and Part IV, Item 15 of its Annual Report on Form 10-K for the year ended December 31, 2024.
- The amendment includes XBRL tagging for Item 10, Directors, Executive Officers and Corporate Governance.
- The amendment also corrects an exhibit by including the Company's Insider Trading Policy as Exhibit 19.1, replacing the previously included Related Party Transaction Policy.
- The filing includes currently dated certifications from the principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- The original 10-K was filed with the SEC on March 3, 2025.
- As of January 31, 2025, the registrant had 671,550,270 shares of its common stock outstanding.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, indicating standard corporate governance practices. The sentiment is neutral to slightly positive as it reflects adherence to regulations and transparency.
Positives
- The company is taking steps to ensure compliance with SEC regulations by including XBRL tagging.
- The correction of the exhibit demonstrates attention to detail and accuracy in reporting.
Industry Context
This filing is a routine amendment to correct an error and ensure compliance with SEC regulations, which is a standard practice for publicly traded companies.
Comparison to Industry Standards
- Filing amendments to correct errors and include XBRL tagging is a common practice among publicly traded companies to ensure compliance with SEC regulations.
- Many companies, such as Teva Pharmaceutical Industries Ltd. and Mylan N.V. (now Viatris Inc.), routinely file similar amendments to their annual reports.
Stakeholder Impact
- The amendment ensures accurate and compliant financial reporting, which benefits shareholders by providing reliable information.
- Employees are subject to the Insider Trading Policy, which promotes ethical conduct and compliance with securities laws.
Next Steps
- The company will file its definitive proxy statement for the 2025 Annual Meeting of Stockholders within 120 days of December 31, 2024.
Key Dates
| Date | Description |
|---|---|
| January 28, 2011 | Agreement and Plan of Merger by and among CURNA, Inc., KUR, LLC, OPKO Pharmaceuticals, LLC, OPKO CURNA, LLC, and certain individuals named therein. |
| December 10, 2010 | Exclusive License Agreement by and between TESARO, Inc. and OPKO Health, Inc. |
| January 14, 2022 | Agreement and Plan of Merger and Reorganization by and among the Company, Sema4 Holdings Corp., Orion Merger Sub I, Inc., Orion Merger Sub II, LLC, GeneDx Inc. and GeneDx Holding 2, Inc. |
| May 9, 2022 | Agreement and Plan of Merger by and among the Company, ModeX Therapeutics, Inc., Orca Acquisition Sub, Inc. and Gary J. Nabel. |
| March 27, 2024 | Asset Purchase Agreement by and among BioReference Health, LLC, OPKO Health, Inc. and Laboratory Corporation of America Holdings. |
| January 9, 2024 | Indenture by and between OPKO Health, Inc. and U.S. Bank Trust Company, National Association, as Trustee. |
| January 4, 2024 | Purchase Agreement by and between the Company and J.P. Morgan Securities LLC. |
| January 4, 2024 | Convertible Note Purchase Agreement by and among the Company and certain investors. |
| July 17, 2024 | Note Purchase Agreement by and among the Company, certain purchasers party thereto, OPKO Biologics Limited, Eirgen Pharma Ltd. and HCR Injection SPV, LLC as agent. |
| December 31, 2024 | End of fiscal year for the report. |
| January 31, 2025 | Date for outstanding shares of common stock. |
| March 3, 2025 | Original filing date of the 10-K. |
| March 21, 2025 | Date of the amended filing (10-K/A). |
Keywords
OPKO Health, 10-K/A, Amendment, XBRL, Insider Trading Policy, Financial Reporting, SEC, Sarbanes-Oxley, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.